Swedish Orphan Biovitrum AB (publ) banner
Financial profile · Q3 FY2026

Growing specialty-medicine portfolio with profitable operations and lumpy cash conversion

Sobi’s multi-year statements show expanding revenue, profitable operations, and recurring operating cash generation, while working-capital demands and episodic investment spending make free cash flow more variable. Large acquired-intangible impairments can also make reported earnings less comparable from period to period.

What is developing

The latest results continued portfolio growth and showed a rebound in reported earnings against a prior-year impairment, while working-capital outflows tempered cash conversion. This is a meaningful movement in reported results, but not evidence that the underlying financial model has changed.

What matters next

Whether inventory and receivables stop absorbing cash and operating cash flow tracks the continued earnings growth.

SEK
Metric FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
801m 1.1B 2.4B 3.3B 4.2B 3.3B 3.3B 3B 4.4B 34m
441m — 484.6m 1.6B 2B 2B 2.4B 3.2B 3.7B 10.1B
165m — (103.3m) 411m — — — — — —
32m 39.6m 45.7m 80m 114m 134m 261m 375m 645m 250m
(765m) 282.4m (458.3m) (5m) 46m 503m 316m 1B 845m 975m
— 28.4m 506.5m 520m 918m 1.1B 673m 641m 307m 1.3B
— 13.9m 18.3m 114m — 324m — 949m 1.1B 726m
(299m) (98m) (250.5m) (1.7B) (1.4B) (334m) (1.5B) (2.7B) (1.5B) (2.5B)
343m 1.3B 2.1B 3.6B 4.9B 5.5B 4.6B 4.5B 7.4B 8.6B
(165m) (139.4m) (577.9m) (9.7B) (3.9B) (370m) (1.5B) (4.9B) (3B) (3.2B)
7m 467k 2.5m (11.9B) (112m) 3m — (17B) (86m) (1.1B)
(158m) (139m) (575.4m) (21.7B) (4B) (367m) (1.5B) (21.9B) (3.1B) (4.3B)
24m 0 — — — — 89m 6.1B 427m 245m
(331m) (500m) (2.1m) 15.8B (1.6B) (4.1B) (2.6B) 11.1B (4.6B) (5.1B)
(1m) — — (1m) 288m (351m) (438m) (203m) 178m 554m
(308m) (500m) (2.1m) 15.8B (1.3B) (4.5B) (2.9B) 17B (4B) (4.3B)
5m (1.3m) 7.4m 9m (13m) 12m 119m (35m) (61m) (46m)
(118m) 692.7m 1.5B (2.3B) (333m) 641m 316m (457m) 235m (98m)
178m 1.2B 1.5B (6.1B) 1.1B 5.1B 3.1B (473m) 4.4B 5.4B